SURPASS trial programme: difference between revisions
Diff·revision 11 → 12·14:00, 16 Dec 2024
Difference between revision 11 and revision 12 of SURPASS trial programme. 6 lines changed; the page grew by 113 bytes.
| Revision 11 — 00:17, 26 Nov 2024 GastroparesisGwen (talk) cite the trial publication rather than the sponsor press release 3,661 bytes +34 | Revision 12 — 14:00, 16 Dec 2024 CiteBot (talk) bot: normalise trial registration identifier 3,774 bytes +113 | ||
|---|---|---|---|
| 38 | <ref name="ich_e9">International Council for Harmonisation, ''E9(R1): Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> | 38 | <ref name="ich_e9">International Council for Harmonisation, ''E9(R1): Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> |
| 39 | 39 | ||
| + | 40 | == See also == | |
| + | 41 | * [[Tirzepatide]] | |
| + | 42 | * [[SURMOUNT trial programme]] | |
| + | 43 | * [[Semaglutide]] | |
| + | 44 | * [[SUSTAIN trial programme]] | |
| + | 45 | ||
| 40 | {{DEFAULTSORT:SURPASS trial programme}} | 46 | {{DEFAULTSORT:SURPASS trial programme}} |
| 41 | [[Category:Clinical trial programmes]] | 47 | [[Category:Clinical trial programmes]] |